Edition:
United Kingdom

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

242.40CHF
4:31pm GMT
Change (% chg)

CHF-4.00 (-1.62%)
Prev Close
CHF246.40
Open
CHF246.90
Day's High
CHF247.20
Day's Low
CHF241.60
Volume
322,012
Avg. Vol
357,840
52-wk High
CHF278.40
52-wk Low
CHF164.23

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 0.99
Market Cap(Mil.): CHF19,317.19
Shares Outstanding(Mil.): 74.47
Dividend: 2.55
Yield (%): 0.98

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.64
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Lonza To Establish Cell- And Gene-Therapy Centers Of Excellence

* LONZA TO ESTABLISH CELL- AND GENE-THERAPY CENTERS OF EXCELLENCE TO ACCELERATE GROWTH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

14 Feb 2018

BRIEF-Lonza ‍expands offerings for early phase biopharmaceutical drug development​

* Says ‍expands service offerings for early phase biopharmaceutical drug development​ Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)

02 Nov 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

Lonza buys U.S. clinical manufacturing site from Shire

ZURICH, Oct 3 Lonza Group is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire PLC, the Swiss pharmaceutical ingredients group said on Tuesday without giving the purchase price.

03 Oct 2017

Earnings vs. Estimates